Drug Trial Radar · NCT07678593
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Nov 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Conditions
- Advanced Solid Tumors Cancer
- Pancreatic Ductal Adenocarcinoma
- RAS Mutation
Interventions
GFH276Drug
Oral GFH276 administered once daily in combination with other study drugs.
CetuximabDrug
Intravenous cetuximab at a dose of 500 mg/m²
Nab paclitaxelDrug
Intravenous nab-paclitaxel at a dose of 125 mg/m².
GemcitabineDrug
Intravenous Gemcitabine at a dose of 1000 mg/m².
FluorouracilDrug
Intravenous Fluorouracil at a dose of 2400 mg/m² via 46-hour infusion.Dosing may follow the above regimen or local institutional standards.
LeucovorinDrug
Intravenous leucovorin at a dose of 400 mg/m².Dosing may follow the above regimen or local institutional standards.
IrinotecanDrug
Intravenous irinotecan at a dose of 150 mg/m².Dosing may follow the above regimen or local institutional standards.
OxaliplatinDrug
Intravenous oxaliplatin at a dose of 85 mg/m².Dosing may follow the above regimen or local institutional standards.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) EventsTime frame: First 28 days (21 days for AG (3-week cycle))
- Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months
- Phase II:Objective Response Rate (ORR)Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- Phase Ib: Number of participants with abnormality in hematology laboratory parametersTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in clinical chemistry laboratory assessmentsTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in body temperatureTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in blood pressureTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in Physical Examination FindingsTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in PR intervalTime frame: up to 24 months
- Phase Ib: Number of participants with abnormality in corrected QT interval using Frederica's formula (QTcF)Time frame: up to 24 months
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Concord Cancer Centre, Concord Repatriation General Hospital, Sydney Local Health District
Concord, New South Wales, Australia · Not yet recruiting
Macquarie University / Clinical Trials Unit
North Ryde, New South Wales, Australia · Recruiting
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia · Not yet recruiting
Monash Health (Monash Medical Centre)
Clayton, Victoria, Australia · Recruiting
Northern Health
Epping, Victoria, Australia · Not yet recruiting
PASO Medical
Frankston, Victoria, Australia · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
The Third Affiliated Hospital (Cancer Hospital) of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.